# Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery

> **NCT01473940** · PHASE1 · COMPLETED · sponsor: **Northwestern University** · enrollment: 21 (actual)

## Conditions studied

- Duct Cell Adenocarcinoma of the Pancreas
- Recurrent Pancreatic Cancer
- Stage III Pancreatic Cancer
- Stage IV Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** ipilimumab
- **DRUG:** gemcitabine hydrochloride
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01473940
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-11
- **Primary completion:** 2014-10-16
- **Final completion:** 2018-05-06
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2020-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01473940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01473940, "Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01473940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*